Anderson CV | 1

CURRICULUM VITAE University of Pittsburgh

Department of Radiology

BIOGRAPHICAL NAME: Carolyn J. Anderson, Ph.D. BIRTH DATE: November 12, 1962 HOME ADDRESS: 5435 Albemarle Ave BIRTH PLACE: Superior, Wisconsin

Pittsburgh, PA 15217 HOME PHONE: 412-904-4574 CITZENSHIP: USA BUSINESS ADDRESS: University of Pittsburgh E-MAIL: andersoncj@upmc.edu

Department of Radiology 100 Technology Drive Bridgeside Point 1 - Suite 452 Pittsburgh, PA 15219

BUSINESS PHONE: 412-624-6887 BUSINESS FAX: 412-624-2598

EDUCATION AND TRAINING UNDERGRADUATE: 1981-1985 University of Wisconsin Superior B.S. – 1985 Chemistry

Superior, WI GRADUATE: 1985-1990 Florida State University Ph.D. – 1990 Inorganic Chemistry Tallahassee, FL

APPOINTMENTS AND POSITIONS ACADEMIC: 1985-1986 Florida State University Teaching Assistant, Chemistry Tallahassee, FL 1986-1990 Florida State University Research Assistant, Chemistry Tallahassee, FL 1990-1992 Mallinckrodt Institute of Radiology Research Associate Washington University School of Medicine St. Louis, MO 1993-1999 Mallinckrodt Institute of Radiology Assistant Professor Washington University School of Medicine St. Louis, MO

Anderson CV | 2

1996-2001 Department of Molecular Biology Assistant Professor And Pharmacology Washington University School of Medicine St. Louis, MO 2000-2006 Mallinckrodt Institute of Radiology Assistant Professor Washington University School of Medicine St. Louis, MO 2000-2008 Department of Molecular Biology and Associate Professor Pharmacology Washington, University School of Medicine St. Louis, MO 2006-2008 Graduate Pathway in Imaging Sciences Co-Director Division of Biology and Biomedical Sciences Washington University 2006-2011 Mallinckrodt Institute of Radiology Professor Washington University School of Medicine St. Louis, MO 2007-2011 Department of Chemistry Professor School of Arts and Sciences Washington University 2008-2011 Department of Biochemistry Professor & Molecular Biophysics Washington University School of Medicine 2008- 2011 Graduate Pathway in Imaging Sciences Director Division of Biology and Biomedical Sciences Washington University 2011-present Department of Radiology Professor University of Pittsburgh 2011-present Molecular Imaging Laboratory Director University of Pittsburgh 2012-preseent Department of Pharmacology and Professor

Chemical Biology 2012-present Department of Bioengineering Professor 2013-present In Vivo Imaging Facility, UPCI Co-Director NON-ACADEMIC:

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES Organization Year The Society of Nuclear Medicine and Molecular Imaging 1991-present

Anderson CV | 3

SMMMI Board of Directors 2010-2013 Radiopharmaceutical Science Council (RPSC) 1993-present

RPSC – Board of Directors 1997-1999; 2006-2008 PET Center of Excellence 2005-2010

PET COE – Board of Directors 2005-2007 Center for Molecular Imaging Innovation and Translation 2005-present

Secretary/Treasurer 2006-2008 Vice President 2008-2010 President 2010-2012 Past President 2012-present

Sub-Chair- Scientific Program Committee 1996, 2012 Member, Committee on Government Relations 2005, 2009 Member, Committee on Councils 2008-2012 Chair, Committee on Ethics 2005-2008 Member, Publications Committee 2009-2012

The American Chemical Society (ACS) 1986-present Division of Nuclear Chemistry and Technology 1993-present

Education Committee 1995-1997 Alternate Councilor 1996-2000

The American Association of Cancer Research (AACR) 1996-present The Society of Radiopharmaceutical Sciences 2001-present

Secretary/Treasurer 2003-2005 Board of Directors 2007-2013

Division of Radiopharmacology 2001-2005 Secretary/Treasurer 2001-2005

Academy of Molecular Imaging 2004-2006 World Molecular Imaging Society 2012-present

HONORS ACS Outstanding Analytical Chemist (UW – Superior) 1984 Fellowship, Summer School in Nuclear Chemistry at 1984 San Jose State University ACS Outstanding Chemist Award (UW – Superior) 1985 Coryell Award for Undergraduate Research in Nuclear Chemistry 1986 Sponsored by the Nuclear Chemistry and Technology Division of the ACS Graduate Student Fellowship 1985-1986 Florida State University Travel Contract 1988-1990 Oak Ridge Associated Universities Fellowship, I.I.K.W. Brussels-Research at the Katholieke Universiteit-Leuven Jan-April 1990 Leuven, Belgium President’s Award in Education 2008 Society of Nuclear Medicine and Molecular Imaging Siemens – Pre-clinical Image of the Year - overall 2012 Michael J. Welch Award 2012 Society of Nuclear Medicine and Molecular Imaging

Anderson CV | 4

Co-Chairperson – State of the Art Molecular Imaging in Cancer Biology 2013, 2015 and Therapy; Joint SNMMI/AACR special conference Siemens – Pre-clinical Image of the Year – Novel Application 2013 Distinguished Investigator of the Academy of Radiology Research 2014 Michael J. Welch Lectureship, Washington University 2015 Patricia Durbin Memorial Lectureship, Lawrence Berkeley Laboratory 2016 PUBLICATIONS

REFEREED ARTICLES:

1. Blaha, SL, Anderson CJ, Choppin GR, Pruett DJ; Evaluation of POCl3 as a solvent for complexation studies. Inorganica Chimica Acta 1989; 156:37-39.

2. Anderson CJ, Deakin MR, Choppin GR, D'Olieslager W, Heerman L, Pruett DJ; Spectroscopy and

electrochemistry of U(IV)/U(III) in basic AlCl3-EMIC. Inorganic Chemistry 1991; 30:4013-4016. 3. DiZio JL, Anderson CJ, Davison A, Ehrhardt GJ, Carlson KE, Welch MJ, Katzenellenbogen JA:

Technetium and rhenium labeled progestins: synthesis, receptor binding and in vivo distribution of an 11β-substituted progestin labeled with technetium-99 and 99m and rhenium 186. Journal of Nuclear Medicine 1992; 33:558-569.

4. Anderson CJ, Connett, JM, Schwarz, SW, Rocque PA, Philpott GW, Guo LW, Zinn KR, Meares CF,

Welch MJ: Copper-64 labeled antibodies for PET imaging. Journal of Nuclear Medicine 1992; 33:1685-1691.

5. Herrero P, Markham J, Weinheimer CJ, Anderson CJ, Welch MJ, Green MA, Bergmann SR:

Quantification of regional myocardial perfusion with generator-produced copper-62-PTSM and positron emission tomography. Circulation 1993; 87:173-183.

6. Anderson CJ, Rocque PA, Weinheimer CJ, Welch MJ: Evaluation of copper-labeled bifunctional

chelate-albumin conjugates for blood pool imaging. Nuclear Medicine and Biology 1993; 20:461-467. 7. Anderson CJ, Woods M, Deutsch E, Deutsch K, Sullivan JC: A kinetic study of the reduction of Np(VI)

and Pu(VI) in carbonate media by tris[1,2-bis(dimethylphosphino)ethane] complexes of Tc(I) and Re(I). Radiochimica Acta 1993; 61:137-139.

8. Chi DY, O’Neil JP, Anderson CJ, Welch MJ, Katzenellenbogen JA. Homodimeric and heterdimeric

bis-aminothiol oxo metal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. Journal of Medicinal Chemistry, 1994; 37:928-937.

9. Schwarz SW, Connett JM, Anderson CJ, Rocque PA, Philpott GW, Guo LW, Welch MJ. Evaluation of

a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody. Nuclear Medicine and Biology, 1994; 21:619-626.

10. Neil JP, Carlson KE, Anderson CJ, Welch MJ, Katzenellenbogen JA. Progestin radiopharmaceuticals

labeled with technetium and rhenium: synthesis, binding affinity and in vivo distribution of a new N2S2-metal conjugate. Bioconjugate Chemistry, 1994; 5:182-193.

Anderson CV | 5

11. Edwards WB, Fields CG, Anderson CJ, Pajeau TS, Welch MJ, Fields GB. Generally applicable, convenient solid phase synthesis and in vitro receptor binding of octreotide analogs. Journal of Medicinal Chemistry, 1994; 37:3749-3757.

12. Katti KK, Singh PR, Volkert WA, Anderson CJ, Welch MJ, Hoffman T, Katti KV, Ketring AR, Wang

M. Synthesis and characterization of a neutral and lipophilic Ph3PN999mTcO3 complex. International Journal of Applied Radiation and Isotopes, 1995; 46:53-58.

13. Anderson CJ, John CS, Li YJ, Hancock RJ, McCarthy TJ, Martell AE, Welch MJ. N,N’-ethylene-di-L-

cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies. Nuclear Medicine and Biology, 1995; 22:165-173.

14. Anderson CJ, Schwarz SW, Connett JM, Cutler PD, Guo LW, Germain CJ, Philpott GW Zinn KR,

Greiner DP, Meares CF, Welch MJ. Preparation, biodistribution, and dosimetry of copper-64-labeled anti-colorectal carcinoma antibody (MAb) fragments 1A3-F(ab’)2. Journal of Nuclear Medicine 1995; 36:850-858.

15. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR, Meares CF, Cutler PD,

Welch MJ, Siegel BA. RadioimmunoPET: Detection of colorectal carcinoma by positron emission tomography with a 64Cu-labeled monoclonal antibody. Journal of Nuclear Medicine 1995; 36:1818-1824.

16. Jones-Wilson TM, Motekaitis RJ, Sun Y, Anderson CJ, Martell AE, Welch MJ. New hydroxybenzyl

and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium (III) and indium (III). Nuclear Medicine and Biology, 1995; 22:859-868.

17. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo

evaluation of copper-64-labeled octreotide conjugates. Journal of Nuclear Medicine, 1995; 36:2315-2325.

18. Cutler PD, Schwarz SW, Anderson CJ, Connett JM, Welch MJ, Philpott GW, Siegel BA. Dosimetry of

64Cu-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. Journal of Nuclear Medicine, 1995; 36:2363-2371.

19. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, Welch MJ.

Identification of metabolites of In-111-DTPA-monoclonal antibodies and antibody fragments in vivo. Cancer Research 1995; 55(23 suppl 5):S5714-S5720.

20. Li Y, Martell AE, Hancock RD, Reibenspies JH, Anderson CJ, Welch MJ. N,N’-ethylendi-L-cysteine

(EC) and its metalcomplexes: synthesis, characterization, crystal structures and equilibrium constants. Inorganic Chemistry, 1996; 35:404-414.

21. Sun Y, Anderson CJ, Pajeau TS, Reichert DE, Hancock RD, Motekaitis RJ, Martell AE, Welch MJ.

Indium(III) and gallium(III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling and in vivo behavior. Journal of Medicinal Chemistry, 1996; 39:458-470.

22. Connett JM, Anderson CJ, Guo LW, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW,

Welch MJ. Radioimmunotherapy with a Cu-64 labeled monoclonal antibody: a comparison with Cu-67. Proceedings of the National Academy of Sciences, U.S.A., 1996; 93:6814-6818.

23. Rogers BE, Anderson CJ, Connett JM, Guo LW, Edwards WB, Sherman ELC, Zinn KR, Welch MJ.

Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjugate Chemistry, 1996; 7:511-522.

Anderson CV | 6

24. Herrero P, Hartman JJ, Green MA, Anderson CJ, Welch MJ, Markham J, Bergmann SR. Assessment of regional myocardial perfusion with generator-produced 62Cu-PTSM and PET in human subjects. Journal of Nuclear Medicine, 1996; 37:1294-1300.

25. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-DTPA-Octreotide is delivered to

pancreatic, tumor cell, renal and hepatocyte lysosomes. Cancer Research, 1997; 57:659-671. 26. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margenau WH, Cutler CS, Anderson CJ, Welch

MJ. The efficient production of high specific activity 64Cu using a biomedical cyclotron. Nuclear Medicine and Biology, 1997; 24:35-43.

27. Downer JB, McCarthy TJ, Edwards WB, Anderson CJ, Welch MJ. Reactivity of p-[18F]fluorophenacyl

bromide for radiolabeling of proteins and peptides. Applied Radiation and Isotopes 1997; 48:907-916. 28. Bass, LA, Lanahan, MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, Anderson CJ.

Identification of the soluble in vivo metabolites of Indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide. Bioconjugate Chemistry, 1998; 9:192-200.

29. Jones-Wilson TM, Deal KA, Anderson CJ, McCarthy DW, Kovacs Z, Motekaitis RJ, Sherry AD,

Martell AE, Welch MJ. The in vivo behavior of copper-64-labeled azamacrocycle complexes. Nuclear Medicine and Biology, 1998; 25:523-530.

30. Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME,

Lewis JS, Schwarz SW. Radiotherapy, toxicity and dosimetry of copper-64-labeled-TETA-octreotide in tumor-bearing rats. Journal of Nuclear Medicine, 1998; 39:1944-1951.

31. Spradau TW, Edwards WB, Anderson CJ, Welch MJ, Katzenellenbogen JA. Synthesis and biological

evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide. Nuclear Medicine and Biology, 1999; 26:1-7.

32. Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, Sharp T, Yonekura Y, Welch MJ.

Comparative studies of Cu-64 ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nuclear Medicine and Biology, 1999; 26:117-121.

33. Lewis JS, Srinivasan, A, Schmidt, MA, Anderson CJ. In vitro and in vivo evaluation of 64Cu-TETA-

Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. Nuclear Medicine and Biology, 1999; 26: 267-273.

34. Cutler CS, Giron MC, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, Quarless DA, Koch SA,

Welch MJ. Evaluation of gallium-68 tris(2-Mercaptobenzyl)amine: a complex with brain and myocardial uptake. Nuclear Medicine and Biology, 1999; 26:305-316.

35. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four 64Cu-

labeled somatostatin analogs in vitro and in a tumor-bearing rat model: evaluation of new derivatives for PET imaging and targeted radiotherapy. Journal of Medicinal Chemistry, 1999; 42:1341-1347.

36. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS,

Anderson CJ, Welch MJ. High purity production and potential applications of copper-60 and copper-61. Nuclear Medicine and Biology, 1999; 26:351-358.

37 Anderson CJ, Choppin GR, Pruett DJ, Costa D, Smith W. Electrochemistry and spectroscopy of UO2

2+ in acidic AlCl3-EMIC. Radiochimica Acta, 1999; 84:31-36.

38. Connett JM, Buettner TL, Anderson CJ. Maximum tolerated dose and large tumor radioimmunotherapy

studies of 64Cu-labeled Mab 1A3 in a colon cancer model. Clinical Cancer Research, 1999; 5:3207s-3212s.

Anderson CV | 7

39. Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SVS, Anderson CJ,

Chappell LL, Brechbiel MW, Curiel DT. Targeting Strategies for Cancer Radiotherapy. Clinical Cancer Research, 1999; 5:3048s-3055s.

40. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP,

Anderson CJ. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive tumor-bearing rat model. Clinical Cancer Research, 1999; 5:3608-3616.

41. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-

octreotide to superoxide dismutase in rat liver. Bioconjugate Chemistry, 2000; 11:527-532. 42. Cutler CS, Wuest M, Anderson CJ, Reichert DE, Sun Y, Martell AE, Welch MJ. Labeling and In Vivo

Evaluation of Novel Copper(II) Dioxotetraazamacrocyclic Complexes. Nuclear Medicine and Biology, 2000; 27:375-380.

43. Lewis JS, Laforest R, Lewis MR, Anderson CJ. Comparative dosimetry of copper-64 and yttrium-90-

labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy and Radiopharmaceuticals, 2000; 15:593-604.

44. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.

Copper-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. Journal of Nuclear Medicine, 2001; 42:213-221.

45. Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and

dosimetry of 177Lu-DOTA-Y3-octreotate in a rat model. International Journal of Cancer, 2001; 94:873-877.

46. Edwards WB, Anderson CJ, Fields GB, Welch MJ. Evaluation of radiolabeled type IV collagen

fragments as potential tumor imaging agents. Bioconjugate Chemistry, 2001; 12:1057-1065. 47. Lewis MR, Boswell CA, Laforest R, Buettner TL, Ye D, Connett JM, Anderson CJ. Conjugation of

monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3. Cancer Biotherapy and Radiopharmaceuticals, 2001; 16: 483-494.

48. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, Motekaitis R, Martell AE, Welch MJ,

Anderson CJ. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged ligands. Journal of Medicinal Chemistry, 2002; 45:469-477.

49. Li WP, Lewis JS, Kim J, Bugaj JE, Erion JL, Johnson ML, Anderson CJ. DOTA-D-Tyr1-Octreotate: a

somatostatin analog for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjugate Chemistry, 2002; 13:721-728.

50. Sun X, Wuest M, Kovacs Z, Sherry AD, Motekaitis R, Wang Z, Martell AE, Welch MJ, Anderson CJ.

In Vivo Behavior of Copper-64-Labeled Methanephosphonate Tetraazamacrocyclic Ligands. Journal of Biological Inorganic Chemistry, 2003; 8:217-225.

51. Ye Y, Li WP, Anderson CJ, Kao J, Nikiforovich G, Achilefu S. Synthesis and characterization of a

near-infrared optical scaffold. Journal of the American Chemical Society, 2003; 125:7766-7767. 52. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ.

In vivo Evaluation of Pre-targeted Copper-64 for Tumor Imaging and Therapy. Journal of Nuclear Medicine, 2003; 44:1284-1292.

Anderson CV | 8

53. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogs: implications for cancer therapy. Cancer Research, 2003; 63:6864-6869.

54. Boswell CA, Sun X, Niu W, Wong EH, Weisman GR, Rheingold AL, Anderson CJ. Comparative in

vivo Stability of Copper-64-Labeled Cross-bridged and Conventional Tetraazamacrocyclic Complexes. Journal of Medicinal Chemistry, 2004; 47:1465-1474.

55. Niu W, Wong EH, Weisman GR, Peng Y, Anderson CJ, Zhakarov LN, Golen JA, Rheingold AL.

Structure and dynamic studies of the zinc and gallium complexes of dicarboxylate pendant-armed cross-bridged cyclen. European Journal of Inorganic Chemistry, 2004: 3310-3315.

56. Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, and Anderson CJ.

Development of a Two-Antibody Model for Evaluation of Copper-64 Radioimmunotherapy. Veterinary and Comparative Oncology, 2004; 2:82-90.

57. Sun X, Kim J, Martell AE, Welch MJ, Anderson CJ. In Vivo Evaluation of Copper-64-Labeled

Monoxo-Tetraazamacrocyclic Ligands. Nuclear Medicine and Biology, 2004; 8:1049-1057. 58. Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ. Preparation and

Biological Evaluation of Copper-64-labeled Tyr3-octreotate using a Cross-Bridged Macrocyclic Chelator. Clinical Cancer Research, 2004; 10:8674-8682.

59. Boswell CA, McQuade P, Weisman GR, Wong EH, Anderson CJ. Optimization of Labeling and

Metabolite Analysis of Copper-64-Labeled Azamacrocyclic Chelators by Radio-LC-MS. Nuclear Medicine and Biology, 2005; 32:29-38.

60. Yoo J, Reichert DE, Kim JY, Anderson CJ, Welch MJ. A potential Dubin-Johnson syndrome imaging

agent: Synthesis, biodistribution, and microPET imaging. Molecular Imaging, 2005; 4:18-29. 61. Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, Lewis MR. Comparative

uptakes and biodistributions of internalizing versus non-internalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nuclear Medicine and Biology, 2005; 32:851-858.

62. Woodin KS, Heroux KJ, Boswell CA, Wong EH, Weisman GR, Niu W, Tomellini SA, Anderson CJ,

Zakharov LN, Rheingold AL. Kinetic inertness and electrochemical behavior of Cu(II) tetraazamacrocyclic complexes: possible implications for in vivo stability. European Journal of Inorganic Chemistry, 2005; 23:4829-4833.

63. Shen X, Boswell CA, Wong EH, Weisman GR, Anderson CJ, Tomellini SA. Investigation of Cu-

Azamacrocyclic Complexes by HPLC. Biomedical Chromatography, 2006; 20:37-47. 64. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix

metalloproteinase expression in metastatic tumor models. Nuclear Medicine and Biology, 2006; 33:227-237.

65. Wadas TJ, Anderson CJ. Labeling of TETA-and CB-TE2A-conjugated peptides with copper-64. Nature

Protocols, 2006; 1:3062-3068. 66. Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, Teitelbaum SL, Anderson CJ.

Non-invasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a 64Cu-labeled RGD Peptide. Journal of Nuclear Medicine, 2007; 48: 311-318.

67. Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, Rogers BE.

Characterization of Somatostatin Receptor Subtype 2 Expression in Stably Transfected A-427 Human Cancer Cells. Molecular Imaging, 2007; 6:56-67.

Anderson CV | 9

68. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR, Wong EH, Golen JA,

Rheingold AL, Anderson CJ. Synthesis, Characterization and in vivo Studies of Cu(II)-64-labeled Cross-bridged Tetraazamacrocycle-amide Complexes as Models of Peptide Conjugate Imaging Agents. Journal of Medicinal Chemistry, 2007; 50:2527-2535.

69. Heroux KJ, Woodin KS, Tranchemontagne DJ, Widger PCB, Southwick EA, Wong EH, Weisman GR,

Tomellini SA, Wadas TJ, Anderson CJ, Kassel S, Golen JA, Rheingold AL. The Long and Short of It: The Influence of N-Carboxyethyl versus N-Carboxymethyl Pendant Arms on in vitro and in vivo Behavior of Copper Complexes of Cross-bridged Tetraamine Macrocycles. Dalton Transactions, 2007; 2150-2162.

70. Eiblmaier M, Andrews R, Laforest R, Rogers BE, Anderson CJ. Nuclear Uptake and Dosimetry of

64Cu-labeled Chelator-Somatostatin Conjugates in a SSTr2-transfected Human Tumor Cell Line. Journal of Nuclear Medicine, 2007; 1390-1396.

71. Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, Anderson CJ, Achilefu S. The

agonist-antagonist dilemma in molecular imaging: Evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjugate Chemistry, 2008; 19:192-200

72. Eiblmaier M, Meyer LA, Anderson CJ. The Role of p53 in the Trafficking of Copper-64 to Tumor Cell

Nuclei. Cancer Biology and Therapy, 2008; 7:63-69. 73. Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor binding, biodistribution and

metabolism studies of 64Cu-DOTA-cetuximab, a PET imaging agent for epidermal growth factor receptor positive tumors. Cancer Biotherapy and Radiopharmaceuticals, 2008; 23:158-171.

74. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR

expression with receptor binding properties and internalization of 64Cu-DOTA-C225 in five cervical cancer cell lines. Journal of Nuclear Medicine, 2008; 49:1472-1479.

75. Wadas TJ, Eiblmaier M, Zheleznyak A, Sherman CD, Ferdani R, Liang K, Achilefu S, Anderson CJ.

Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor positive tumors. Journal of Nuclear Medicine, 2008; 49:1819-1827.

76. Papini G, Alidori S, Lewis JS, Reichert DE, Pellei M, Gioia Lobbia G, Biddlecomb GB, Anderson CJ,

Santini C. Synthesis and Characterization of the Copper(II) Complexes of New N2S2-donor Macrocyclic Ligands: Synthesis and In Vivo Evaluation of the 64Cu Complexes. Dalton Transactions, 2009; 177-184.

77. Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D,

Anderson CJ, Welch MJ, Fréchet JMJ. Biodegradable dendritic positron emitting nanoprobes for the non invasive imaging of angiogenesis. Proceedings of the National Academy of Sciences USA, 2009; 106:685-690.

78. DeNardo SJ, Liu R, Albrecht H, Natarajan A, Sutcliffe JL, Anderson CJ, Peng L, Yuan A, Ferdani R,

Cherry SR, Lam KS. 111In-LLP2A-DOTA PEG Targeting α4β1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies. Journal of Nuclear Medicine, 2009; 50:625-634.

79. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. 64Cu-Labeled CB-TE2A and

Diamsar Conjugated RGD Peptide Analogs for Targeting Angiogenesis: Comparison of their Biological Activity. Nuclear Medicine and Biology, 2009; 36:277-285.

80. Hausner SH, Kukis, DL, Gagnon KJ, Stanecki CE, Ferdani R, Marshall JF, Anderson CJ, Sutcliffe JL.

Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelators for targeted PET imaging with an αvβ6-specific peptide. Molecular Imaging, 2009; 8:111-121.

Anderson CV | 10

81. Berezin MY, Guo K, Teng B, Edwards WB, Anderson CJ, Vasalatiy O, Gandjbakhche A, Griffiths GL, Achilefu S. Radioactivity-synchronized fluorescence enhancement using a radionuclide fluorescence-quenched dye. Journal of the American Chemical Society, 2009; 131:9198-9200.

82. Barnard PJ, Holland JP, Bayly SR, Wadas TJ, Anderson CJ, Dilworth JR. Macrocyclic diamide ligand

systems: potential chelators for 64Cu and 68Ga-based SPECT and PET imaging agents. Inorganic Chemistry, 2009; 48:7117-7126.

83. Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the αvβ3

integrin for small animal PET/CT imaging of osteolytic bone metastases. Journal of Nuclear Medicine, 2009; 50:1873-1880

84. Stigers DJ, Ferdani R, Weisman GR, Wong EH, Anderson CJ, Golen JA, Moore C, Rheingold AL. A

new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper(II) binding for radiopharmaceutical applications. Dalton Transactions, 2010; 39:1699-1701.

85. Seo JW, Mahakian LM, Kheirolomoom, A, Zhang H, Meares CF, Ferdani R, Anderson CJ, Ferrara KW.

Liposomal Cu-64 labeling method using bifunctional chelators: polyethylene glycol spacer and chelator effects. Bioconjugate Chemistry, 2010; 21:1206-1215.

86. Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The Biodistribution of [153Gd]Gd-

Labeled Magnetic Resonance Contrast Agents in a Transgenic Mouse Model of Renal Failure Differs Greatly from Control Mice. Magnetic Resonance in Medicine, 2010; 64:1274-1280.

87. Kumar SR, Gallazzi FA, Figueroa SD, Ferdani R, Anderson CJ, Deutscher SL. In Vitro and In Vivo

Evaluation of 64Cu-radiolabeled KCCYSL Peptides for Targeting of ErbB-2 Expressing Breast Carcinomas. Cancer Biotherapy and Radiopharmaceuticals, 2010; 25:693-703.

88. Shokeen M, Pressly ED, Hagooly A, Zheleznyak A, Ramos N, Fiamengo AL, Welch MJ, Hawker CJ,

Anderson CJ. Evaluation of multivalent, multi-functional polymeric nanoparticles for imaging applications. ACS Nano, 2011; 5:738-747.

89. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ,

Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. Journal of Nuclear Medicine, 2011; 52:470-477.

90. Odendaal AY, Fiamengo AL, Ferdani R, Wadas TJ, Hill DC, Peng Y, Heroux KJ, Golen JA, Rheingold

AL, Anderson CJ, Weisman GR, Wong EH. A Trimethylene versus an Ethylene Cross-bridged Tetraazamacrocycle and in vitro/in vivo Comparisons of their Copper(II) Complexes. Inorganic Chemistry, 2011; 50:3078-86.

91. Bryan JN, Jia F, Mohsin H, Sivaguru G, Anderson CJ, Miller WH, Henry CJ, Lewis MR. Monoclonal

antibodies for copper-64 PET dosimetry and radioimmunotherapy. Cancer Biology and Therapy, 2011; 11:1001-1007.

92. Nguyen K, Parry JJ, Rogers BE, Anderson CJ. Evaluation of copper-64-labeled somatostatin agonists

and antagonist in sstr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy. Nuclear Medicine and Biology, 2012; 39:187-197.

93. Ferdani R, Stigers DJ, Fiamengo AL, Wei L, Li BTY, Golen JA, Rheingold AL, Weisman GL, Wong

EH, Anderson CJ. Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms. Dalton Transactions, 2012; 41:1938-1950.

94. Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ.

Integrin αvβ3 as a PET Imaging Biomarker for Osteoclast Number in Mouse Models of Negative and Positive Osteoclast Regulation. Molecular Imaging and Biology, 2012; 14:500-508.

Anderson CV | 11

95. Shokeen M, Zheleznyak A, Wilson JM, Jiang M, Liu R, Ferdani R, Lam KS, Schwarz JK, Anderson

CJ. Molecular imaging of very late antigen-4 (α4β1 integrin) in the pre-metastatic niche. Journal of Nuclear Medicine, 2012; 53:779-786.

96. Guo Y, Ferdani R, Anderson CJ. Preparation and biological evaluation of 64Cu-labeled Tyr3-

octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator. Bioconjugate Chemistry, 2012; 23:1470-1477.

97. Ndinguri MW, Zheleznyak A, Lauer JL, Anderson CJ, Fields GB. Application of collagen-model

triple helical peptide-amphiphiles for CD44-targeted drug delivery systems. Journal of Drug Delivery. 2012; 2012:592602. Epub 2012 Nov 14

98. Jiang M, Ferdani R, Shokeen M, Anderson, CJ. Comparison of two cross-bridged macrocyclic

chelators for the radiochemical and biological evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors. Nuclear Medicine and Biology, 2013; 40:245-51.

99. Soodgupta D, Hurchla M, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH,

Shokeen M. Very late antigen-4 (α4β1 integrin) targeted PET imaging of multiple myeloma. PLoS ONE 2013; 8(2): e55841. doi:10.1371/journal.pone.0055841.

100. Zeng D, Anderson CJ. Rapid and sensitive LC-MS approach to quantify non-radioactive transition

metal impurities in metal radionuclides. Chemical Communications, 2013, 49: 2697-2699. 101. Guo Y, Parry JJ, Laforest R, Rogers BE, Anderson CJ. The role of p53 on combination

radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. Journal of Nuclear Medicine, 2013; 54:1621-1629.

102. Zeng D, Qin O, Cai Z, Xie X-Q, Anderson CJ. New cross-bridged cyclam derivative CB-TE1K1P,

an improved bifunctional chelator for copper radionuclides. Chemical Communications, 2014, 50:43-45. ***Featured on Inside Cover of ChemComm***

103. Beaino W, Guo Y, Chang A, Anderson CJ. Roles of Atox1 and p53 in the trafficking of copper-64 to

tumor cell nuclei: implications for cancer therapy. Journal of Biological and Inorganic Chemistry, 2014, 19:427-438.

104. Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, Mease RC, Pomper

MG. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. Journal of Medicinal Chemistry, 2014; 57:2657-2669.

105. Hu LY, Bauer N, Knight LM, Liu S, Li Z, Anderson CJ, Conti PS, Sutcliffe JL. Characterization and

evaluation of 64Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ6. Molecular Imaging and Biology, 2014; 16:567-577.

106. Cai Z, Ouyang Q, Zeng D, Nguyen KN, Modi J, Wang L, White AG, Rogers BE, Xie, X-Q, Anderson

CJ. 64Cu-labeled somatostatin analogs conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studies. Journal of Medicinal Chemistry, 2014; 57:6019-29.

107. Zeng D, Guo Y, White AG, Cai Z, Modi J, Ferdani R, Anderson CJ. Comparison of conjugation

strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice. Molecular Pharmaceutics, 2014; 11:3980-3987

108. Nedrow JN, White AG, Modi J, Nguyen K, Chang AJ, Anderson CJ. PET imaging of Copper-64 and

Gallium-68 Labeled Chelator Conjugates of the Somatostatin Agonist, Tyr3-octreotate. Molecular Imaging, 2014; 13:1-13.

Anderson CV | 12

109. Beaino W, Anderson CJ. PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of

Gallium-68- and Copper-64-labeled NODAGA and CB-TE1A1P-LLP2A Conjugates. Journal of Nuclear Medicine, 2014; 55:1856-1863.

110. Lux J, White AG, Chan M, Anderson CJ*, Almutairi A*. Nanogels from Metal-Chelating Crosslinkers

as Versatile Platforms Applied to Copper-64 PET Imaging of Tumors and Metastases. Theranostics, 2015; 3: 277-288. (*co-corresponding authors)

111. Ocak M, Gillman AG, Bresee J, Zhang L, Vlad AM, Mueller C, Schibli R, Edwards WB, Anderson

CJ, Gach HM. Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model. Molecular Pharmaceutics, 2015; 12:542-53.

112. Cai Z, Li BTY, Wong EH, Weisman GR, Anderson CJ. Cu(I)-assisted Click Chemistry Strategy for

Conjugation of Non-protected Cross-bridged Macrocyclic Chelators to Tumour-targeting Peptides. Dalton Transactions, 2015, 44, 3945 – 3948.

113. Zhang S, Shao P, Ling X, Yang L, Hou W, Thorn SH, Beaino W, Anderson CJ, Ding Y, Bai M. In

vivo Inflammation Imaging using a CB2R-targeted Near Infrared Fluorescent Probe. American Journal of Nuclear Medicine and Medical Imaging, 2015; 5:246-258.

114. Beaino W#, Nedrow J#, Anderson CJ. Evaluation of 68Ga- and 177Lu-DOTA-PEG4-LLP2A for VLA-

4 targeted PET imaging and treatment of metastatic melanoma. Molecular Pharmaceutics, 2015; 12:1929-1938. (#These two authors contributed equally)

115. Patel SK#, Beaino W#, Anderson CJ*, Janjic JM*. Theranostic nanoemulsions for macrophage COX-

2 inhibition in a murine inflammation model. Clinical Immunology, 2015; 160:59-70. (#These two authors contributed equally; *co-corresponding authors).

116. Song J, Cai Z, White AG, Jin T, Wang X, Kadayakkara D, Anderson CJ, Ambrose Z, Young W-B.

Visualization and quantification of simian immunodeficiency virus (SIV)-infected cells using non-invasive molecular imaging. Journal of General Virology, 2015; 96:3131-3142.

117. Sun L, Gai Y, Anderson CJ, Zeng D. Highly efficient and versatile fluorous-tagged Cu(I) catalyzed

azide-alkyne cycloaddition ligand for preparing bioconjugates. ChemComm, 2015; 51:17072-17075 118. Cai Z, Mason NS, Anderson CJ, Edwards WB. Synthesis and preliminary evaluation of an 18F-labeled

oleic acid analog for PET imaging of fatty acid uptake and metabolism. Nuclear Medicine and Biology; 2016; 43:108-115.

119. Soodgupta D, Zhou H, Beaino W, Lu L, Snee M, Rettig M, Skeath J, DiPersio JF, Akers WJ, Laforest

R, Weilbaecher K, Anderson CJ, Tomasson MH, Shokeen M. Ex Vivo and In vivo evaluation of over-expressed VLA-4 using LLP2A imaging agents. Journal of Nuclear Medicine 2016; 57:640-645.

120. Nedrow JR, Day KE, Latoche JD, Modi J, Ganguly T, Zeng D, Kurland BF, Berkman CE, Anderson

CJ. Targeting PSMA with a 64Cu-labeled phosphoramidate inhibitor for PET/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer. Molecular Imaging and Biology, published on-line November 9, 2015; doi:10.1007/s11307-015-0908-7.

REVIEWS, INVITED PUBLISHED PAPERS, PROCEEDINGS OF CONFERENCE AND SYMPOSIA,

MONOGRAPHS, BOOKS and BOOK CHAPTERS:

Anderson CV | 13

1. Schwarz SW, Anderson CJ, Welch MJ: Radiochemistry and radiopharmacology. In Nuclear Medicine Technology and Techniques, 3rd Ed., DR Bernier, P Christian, LD Wells (eds), Mosby Year Book, St. Louis 1994, pp.142-161.

2. Anderson CJ, Welch MJ: Gallium. In Handbook on Metals in Clinical and Analytical Chemistry, H.G.

Seiler, A. Sigel, H. Sigel (eds), Marcel Dekker, Inc., New York 1994, pp. 371-380. 3. Anderson CJ, Schwarz SW, Welch MJ: Indium. In Handbook on Metals in Clinical and Analytical

Chemistry, H.G. Seiler, A. Sigel, H. Sigel (eds), Marcel Dekker, Inc., New York 1994, pp. 401-408. 4. Anderson CJ, Bergmann SR. In search of the perfect PET flow tracer [editorial]. Journal of Nuclear

Medicine, 1994; 35:1122-1124. 5. Schwarz SW, Anderson CJ, Downer JB. Radiochemistry and Radiopharmacology. In Nuclear Medicine

Technology and Techniques, 4th Ed., DR Bernier, P Christian, JK Langan (eds), Mosby Year Book, St. Louis, 1997.

6. Reichert DE, Anderson CJ, Welch MJ. Metal radionuclides for imaging and therapy. Chemistry and

Industry, September 21, 1998 p. 730-733. 7. Reichert DE, Lewis JS, Anderson CJ. Metal Complexes as Diagnostic Tools. Coordination Chemistry

Reviews 1999; 184:3-66. 8. Cutler CS, Lewis JS, Anderson CJ. Utilization of Metabolic, Transport and Receptor-Mediated

Processes to Deliver Agents for Cancer Diagnosis. Advanced Drug Delivery Reviews 1999; 37:189-212. 9. Anderson CJ, Welch MJ. Radiometal-labeled agents (non-technetium) for diagnostic imaging.

Chemical Reviews, 1999; 99:2219-2234. 10. Lewis JS, Lewis, MR, Srinivasan A, Schmidt MA, Anderson CJ. Structure-activity studies of Cu-64-

labeled somatostatin analogs for diagnostic imaging and targeted radiotherapy. Technetium, Rhenium and Other Radiometals in Chemistry and Nuclear Medicine, 5th Ed., M Nicolini and U Mazzi (eds), Servizi Grafici Editoriali, Padova, 1999, pp. 53-58.

11. Welch MJ, Reichert DE, Anderson CJ, Martell AE. Chemistry of gallium, indium and copper in the

design of new radiopharmaceuticals. Technetium, Rhenium and Other Radiometals in Chemistry and Nuclear Medicine, 5th Ed., M Nicolini and U Mazzi (eds), Servizi Grafici Editoriali, Padova, 1999, pp. 43-52.

12. Edwards WB, Anderson CJ, Fields GB, Welch MJ. Evaluation of collagen-based peptides as imaging

agents for α3β1 integrin. Technetium, Rhenium and Other Radiometals in Chemistry and Nuclear Medicine, 5th Ed., M Nicolini and U Mazzi (eds), Servizi Grafici Editoriali, Padova, 1999, pp. 527-532.

13. Anderson CJ, Lewis JS. Radiopharmaceuticals for targeted radiotherapy of cancer. Expert Opinion in

Therapeutic Patents, 2000:10:1057-1069. 14. Blankenberg FG, Eckelman WC, Strauss W, Welch MJ, Alavi A, Anderson CJ, Bacharach S, Blasberg

RG, Graham MM, Weber W. Role of radionuclide imaging in trials of antiangiogenic therapy. Academic Radiology, 2000; 7:851-867.

15. Anderson CJ. Metabolism of radiometal-labeled proteins and peptides: what are the real

radiopharmaceuticals in vivo? [editorial] Cancer Biotherapy and Radiopharmaceuticals, 2001; 16:451-455

Anderson CV | 14

16. Anderson CJ, Green MA, Fujibayashi Y. Chemistry of Copper Radionuclides and Radiopharmaceutical Products. In Handbook of Radiopharmaceuticals: Radiochemistry and Applications, MJ Welch and C. Redvanly (eds). John Wiley & Sons, Ltd., 2003, pp 401-422.

17. Piwnica-Worms, D., Luker, G.D., Anderson, C.J., Wahl, R.L. Molecular Imaging in Oncology. In:

Molecular Nuclear Medicine: The Challenge from the Human Genome. Feinendegen, L.E., Shreeve, W.W., Eckelman, W.C., Bahk, Y-W., Wagner, Jr., H.N. (editors), Springer-Verlag, Germany, 2003, pp 633-652.

18. Schwarz SW, Anderson CJ. Radiochemistry and Radiopharmacology. In Nuclear Medicine Technology

and Techniques, 5th Ed., DR Bernier, P Christian, JK Langan (eds), Mosby Year Book, St. Louis, 2003, pp 157-183.

19. Li WP, Anderson CJ. Imaging matrix metalloproteinase expression in tumors. Quarterly Journal of

Nuclear Medicine, 2003, 47:201-208. 20. Madden EF, Anderson CJ, Goering PL. Indium. In Elements and Their Compounds in the

Environment, 2nd Ed., M. Anke, M. Ihnat and M. Stoeppler (Eds), WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2004, pp. 801-809.

21. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods in

Enzymology, 2004; 386:237-261. 22. Li WP, Meyer LA, Anderson CJ. Radiopharmaceuticals for PET imaging of somatostatin receptor

positive tumors. Topics in Current Chemistry, 2005; 252:179-192. 23. Edwards WB, Liang K, Xu B, Anderson CJ, Achilefu S. Synthesis and radiolabeling of a somatostatin

analog for multimodal imaging. Proceedings of SPIE-The International Society for Optical Engineering (2006), 6097(Optical Molecular Probes for Biomedical Applications).

24. Fiamengo AL, Capretto DA, Sprague JE, Peng Y, Weisman GR, Wong EH, Anderson CJ. In vivo

evaluation of 64Cu-labeled cross-bridged tetraazamacrocyclic complexes with amide and/or carboxylate functional groups. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, 7th Ed., U Mazzi (ed), Servizi Grafici Editoriali, Padova, 2006, pp. 235-236.

25. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Development of Chelators for Copper-64

Radiopharmaceuticals: Optimizing for in vivo Stability. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, 7th Ed., U Mazzi (ed), Servizi Grafici Editoriali, Padova, 2006, pp. 215-218.

26. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper

radiopharmaceuticals. Current Pharmaceutical Design, 2007; 13:3-16. 27. Lewis JS, Anderson CJ. Radiometal-labeled somatostatin analogues for applications in cancer imaging

and therapy. In Methods in Molecular Biology (Peptide Characterization and Application Protocols), G.B. Fields (Ed), Volume 386. Humana Press (Totowa, NJ), 2007 pp. 227-240.

28. Anderson CJ. Imaging matrix metalloproteinase expression: applications for cardiovascular imaging. In

Textbook of Cardiovascular Imaging, R.J. Gropler, D.K. Glover, A.J. Sinusas and H. Taegtmeyer (Eds), Informa Healthcare USA Inc., 2007 pp 303-308.

29. Schwarz SW, Anderson CJ. Radiochemistry and Radiopharmacology. In Nuclear Medicine and

PET/CT: Technology and Techniques, 6th Ed. P Christian, KM Waterstram-Rich (eds), Mosby Elsevier, St. Louis, 2007.

Anderson CV | 15

30. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2008; 52:185-192.

31. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase

overexpression in tumors. Current Pharmaceutical Design, 2008; 2983-2998. 32. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper Radiopharmaceuticals and

positron emission tomography (PET). Accounts of Chemical Research, 2009; 42:832-841. 33. Holland JP, Ferdani R, Anderson CJ, Lewis, JS. Copper-64 radiopharmaceuticals for oncologic

imaging. PET Clinics, 2009; 4:49-67. 34. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals and PET imaging of cancer: advances in pre-

clinical and clinical research. Cancer Biotherapy and Radiopharmaceuticals, 2009; 24:379-393. 35. Anderson CJ, Bulte JWM, Chen K, Chen X, Khaw B-A, Shokeen M, Wooley KL, VanBrocklin HF.

Design of targeted cardiovascular molecular imaging probes. Journal of Nuclear Medicine, 2010; 51:3S-17S.

36. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium,

indium, yttrium and zirconium for PET and SPECT imaging of disease. Chemical Reviews, 2010; 110:2858-2902.

37. Ferdani R, Guo Y, Stigers DJ, Fiamengo AL, Wei L, Golen JA, Rheingold AL, Wong EH, Weisman GR,

Anderson CJ. Cu(II) complexation, 64Cu-labeling and biological evaluation of CB-TE1A1P. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, U Mazzi, WC Eckelman and WA Volkert (eds), Servizi Grafici Editoriali, Padova, 2010, pp. 183-186.

38. Guo Y, Zheleznyak A, Anderson CJ. Relationship between cisplatin, copper-64 radiopharmaceuticals

and p53 in the trafficking of 64Cu to the nuclei of tumor cells. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, U Mazzi, WC Eckelman and WA Volkert (eds), Servizi Grafici Editoriali, Padova, 2010, pp. 353-355.

39. Shokeen M., Pressly E, Connal L, Liu Y, Hawker CJ, Woodard PK, Anderson CJ, Achilefu S, Welch

MJ. Multi-modal in cellulo evaluation of NPR-C targeted C-ANF-peptide and C-ANF-comb nanoparticles. Proc. SPIE 8233, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications IV, 82330U (February 9, 2012); doi:10.1117/12.914991.

40. Schwarz SW, Oyama R, Anderson CJ. Radiochemistry and Radiopharmacology. In Nuclear Medicine

and PET/CT: Technology and Techniques, 7th Ed., P Christian, KM Waterstram-Rich (eds), Elsevier, St. Louis, 2012.

41. Zeng D, Zeglis BM, Lewis JS, Anderson CJ. The Growing Impact of Bioorthogonal Click Chemistry

on the Development of Radiopharmaceuticals. Journal of Nuclear Medicine, 2013; 54:829-832.

42. Zeng D, Anderson CJ. Production and purification of metal radionuclides for PET imaging of disease. Ion Exchange and Solvent Extraction, 2013; 31:337-344.

43. Cai Z, Anderson CJ. Chelators for copper radionuclides in PET radiopharmaceuticals. Journal of

Labelled Compounds and Radiopharmaceuticals, 2014; 57:224-230.

44. Shakir M, Tang D, Zeh HJ, Tang SW, Anderson CJ, Bahary N, Lotze MT. Finding Flow: The Chemokine Receptors CXCR4/CXCR7 and Their Primary Heterodimeric Ligands CXCL12 and CXCL12/HMGB1 in Pancreatic Cancer Growth and Development. Pancreas, 2015; 44:528-534.

Anderson CV | 16

45. Nedrow JR, Anderson CJ. Emerging Radiometals for PET Imaging. Encyclopedia of Inorganic and

Bioinorganic Chemistry. 2016: DOI: 10.1002/9781119951438.eibc2447

46. Abadjian MC, Edwards, WB, Anderson CJ. Imaging the Tumor Microenvironment. In The Microenvironment in Cancer Progression and Cancer Therapy. P. Kalinski (ed). Springer, New York. In press.

47. Abadjian MC, Choi J, Anderson CJ. Nanoparticles for PET imaging of tumors and cancer metastasis.

In Design and Applications of Nanoparticles in Biomedical Imaging. J. Bulte and M Modo (eds). Springer, New York. In press.

OTHER PUBLICATIONS:

1. Duncan JR, Anderson CJ, Arano Y. Nuclear translocation of somatostatin analogs, Letter to the Editor, Journal of Nuclear Medicine, 2001; 42:529-530.

2. Zinn KR, Anderson CJ, Bradbury M, Cutler CS, Peterson TE, Morgan DE, Price JC, Graham MM,

Contag CH, Wittstrom K, Norenberg JP. Components of a Curriculum for Molecular Imaging Scientists. Journal of Nuclear Medicine (contributed white paper), 2011; 52:650-6.

3. Assuring a Future US-based Nuclear Chemistry Expertise. National Academy of Sciences report; The

National Academies Press, 2012. 4. Zeng D, Anderson CJ. The growing impact of click chemistry on the development of PET

radiopharmaceuticals. MI Gateway Newsletter. 2012; 6:1-4. Patent Application

1. Anderson CJ, Van Houten B, Cai, Zhengxin, Edwards, WB. Fatty Acid Analogs and Their Use. International application No. PCT/US2014/050643, Filed August 12, 2014

Selected SCIENTIFIC PRESENTATIONS and PUBLISHED ABSTRACTS:

1. Ahmed R, Beaino W, Demirci E, Ferris R, Anderson C, Mountz J. Molecular imaging of head and neck xenograft mouse model with [18F] ML-10 and bioluminescence imaging. Journal of Nuclear Medicine, 2014; 55 (suppl 1):1052.

2. Ocak M, Demirci E, Day K, Latoche J, Liu J, Anderson C. Evaluation of 64Cu- and 68Ga-NODAGA-

c(RGDyK) in a rodent inflammatory paw model. Journal of Nuclear Medicine, 2014; 55 (suppl 1):1222.

3. Zeng D, Mattila J, Beaino W, Jiang M, Lopresti B, Coleman M, Flynn J, Anderson C. Copper-64-

labeled CB-TE1K1P conjugates of MCP-1 for PET imaging of macrophages in tuberculosis granulomas. Journal of Nuclear Medicine, 2014; 55 (suppl 1):1210.

4. Demirci E, Ahmed R, Ocak M, Anderson C, Mountz J. Preclinical evaluation of PET imaging

radiotracer, F18-ML-10, for early detection of solid tumor response to chemotherapy. Journal of Nuclear Medicine, 2014; 55 (suppl 1):1066.

5. Nedrow JR, Beaino W, Anderson, CJ. 64Cu-, 68Ga-, and 177Lu-LLP2A conjugates for imaging and

treatment of very late antigen-4 (VLA-4). AACR/SNMMI Joint Conference on Imaging in Cancer Biology. San Diego, CA; February 12, 2015

6. Cai Z, Li B, Wong L, Wong E, Weisman GR, Anderson CJ. Clickable bifunctional cross-bridged

phosphonate-based chelator through alkyne and aldehyde modifications. Journal of Labelled

Anderson CV | 17

Compounds and Radiopharmaceuticals 2015; 58:S143.

7. Clickable Cross-bridged chelator to prepare dimeric peptide for targeted PET imaging. Zeng D, Abadjian M-C, Wiener EC, Grotjahn D, Anderson CJ. Journal of Labelled Compounds and Radiopharmaceuticals 2015; 58:S146.

8. Beaino W, Mattila J, Coleman T, Flynn J, Anderson C. PET Imaging of Immune Cells in a Macaque

Tuberculosis model. Journal of Nuclear Medicine, 2015; 56 (suppl 2):651.

9. Beaino W, Patel S, Herneissy M, Abadjian MC, Janjic J, Anderson CJ. Image-Guided Drug Delivery to Macrophages for Targeting Inflammation. World Molecular Imaging Conference, September, 2015

PROFESSIONAL ACTIVITIES

TEACHING: Course master (or co-course master) of the following courses:

Washington University Biology 5074: Radiopharmaceutical Chemistry and Biology: Spring 2002, Spring 2003 and Spring 2004 Biology 5046: Principles and Applications of Biological Imaging: Spring, 2006; Fall, 2007; Fall, 2008 Biology 5047: Contrast Agents for Biological Imaging: Spring, 2007; Spring, 2008; Spring, 2009; Spring, 2010 University of Pittsburgh Mechanical Engineering 2112: Nuclear Chemistry and Radiochemistry: Spring semester 2013, 2014, 2015

Lecturer for the following courses:

Washington University: Radiochemistry/Radiopharmacy Resident Lectures (1993-2010) Chemistry 555: Special Topics in Organic Chemistry: Nanomedicine; Fall Semester, 2006 Chemistry 454: Inorganic Biochemistry (Fall, 2009)

University of Pittsburgh

Radiology Grand Rounds – May 24, 2011 Bioengineering 2505: Multimodal Biomedical Imaging Technologies: Fall semesters, 2011, 2012, 2013, 2014, 2015 Duquesne University GPSC619: Drug Delivery Systems at Duquesne University, April 14, 2015

GUEST LECTURER POSITIONS Instructor in Radiopharmaceutical Chemistry: Summer School in Nuclear Chemistry, San Jose State University, San Jose, CA: July 24-28, 1995; July 8-12, 1996; July 7-11, 1997; July 6-10, 1998, July 10-13, 2000; July 9-12, 2001; July 7-8, 2003; July 5-6, 2004 Instructor in Radiopharmaceutical Chemistry: Summer School in Nuclear Chemistry, Brookhaven National Laboratory, Upton, NY; July 13-16, 1998 21st Annual AACR Workshop on Molecular Biology in Clinical Oncology, Aspen, CO July 16-22, 2012 MENTORING AND COMMITTEES

Anderson CV | 18

Graduate Student Committees (WU Chemistry): Buck E. Rogers (1995); Michelle Jones-Wilson (1995); Michael Ortworth (1995); Yvette Fobian (1999); Todd Osiek (2000); Mathew Becker (2003); Monica Shokeen (2006); Efram Mebrahtu (2007); Ajay Kshetry (2008); Alina Handorean (2008); Wei Wang (2008); Ruiqiong Li (2009)

Graduate Student Committees (WU DBBS): Michelle Weber (2005); Amy Caruano (2006); Seth Gammon (2007); Sage Arbor (2008); Sharon Lee (2008)

Graduate Student Committees (University of Pittsburgh): Robert DiFazio (2013-) Undergraduate Research Mentor (WU Biology – Honors Program): Ryan Huffman (2002); Shaun Lan (2003); Nicholas Ramos (2008-2009)

Undergraduate Research Mentor (WU Chemistry – Honors Program): Jessica Wilson (2007-2010); Kyle Sutherlin (2008-2010); Re-I Chin (2009-2010) Undergraduate Research Mentor (School of Engineering, Pitt): Erin Dansey (2012-2013); Vineet Agrawal (2013); Matthew Goodwill (2012-2013) High School Student Mentor (through UPCI Scholars): Hunter Crittenden, Mount Lebanon High School, PA External Examiner: Timothy Storr (2005): University of British Columbia Department of Chemistry

Ying Li (2012): University of British Columbia Department of Chemistry Graduate Student Primary Mentor (WU DBBS): C. Andrew Boswell (2004); Current Position: Scientist, Genentech, Inc. South San Francisco, CA Jennifer E. Sprague (2005); Current Position: Instructor in Pediatrics, Washington University, St. Louis, MO

Graduate Student Primary Mentor (WU Chemistry): Ashley L. Fiamengo (2009); Current Position: Chemistry teacher, TMI: The Episcopal School of Texas Kim Nguyen (2010); Current Position: Postdoctoral Researcher, Washington University Yunjun Guo (2012); Current Position: law student, University of Akron Majiong Jiang (2013); Current Position: Air Pollution Specialist, Air Quality Planning and Science Division, Californial Air Resources Board Graduate Student Primary Mentor (Technical University – Dresden, Germany): Martin Eiblmaier (2008); Current position: Biology Teacher at Realschule Schongau Graduate Student Research Mentor (University of Pittsburgh) Priya Balasubramanian (MSTP rotation - 2014) Jaeyeon Choi, Bioengineering PhD student (2015-present) Postdoctoral Researcher Mentor and their current positions: Donald T.T. Yapp (1993-1994); Res Scientist, Department of Advanced Therapeutics, BC Cancer Agency Laura A. Bass (1994-1998); Executive Director, Bristol-Myers Squibb Jason S. Lewis (1996-2000); Chief of Service, Radiochemistry, Memorial Sloan Kettering Cancer Center Michael R. Lewis (2000-2002); Professor, University of Missouri Melinda Wuest (2000-2001); Researcher, University of Alberta Xiankai Sun (2000-2003); Associate Professor, UT-Southwestern Wenping Li (2000-2004); Group Leader, Merck Thaddeus Wadas (2004-2009); Assistant Professor, Director of the Cyclotron Facility, Wake Forest University Monica Shokeen (2006-2010); Assistant Professor, Washington University

Anderson CV | 19

Albert Chang (2009-2011); Assistant Professor of Radiation Oncology, UC-San Francisco Meltem Ocak (2012-2014); Assistant Professor of Pharmaceutical Technology, Istanbul University Emre Demerci (with James Mountz; 2013); Nuclear Medicine Physician, Istanbul University Zhengxin Cai (2011-2015); Associate Research Scientist; Department of Radiology, Yale University Alex White (2012-2014); Staff Scientist, Dept of Molecular Genetics and Microbiology, University of Pittsburgh Jesse Nedrow (2012-2015); Research Instructor, Johns Hopkins University Rafay Ahmed (with James Mountz; 2013-2015); Radiology resident, Geisinger Health System, Danville, PA. Wissam Beaino (2012-2015); Scientist, VU-Amsterdam, The Netherlands Marie Caline Abadjian (2015-) Kinzya Grant (with James Mountz; 2014-) Jongho Kim (with James Mountz; 2015-) Training Programs: PI on 4 grants to develop curriculum and training programs in radiochemistry and molecular imaging

DOE - Graduate Research in Nuclear Medicine at Washington University (2001-2004) NIH - Curriculum for Imaging Sciences at Washington University (2004-2009) NIH - 21st Century Imaging Sciences: Undergraduate and Graduate Student Training (2006-2010) DOE - Integrated Program of Excellence in Nuclear Medicine and Radiochemistry Research (2012-2016)

Team Leader and PI on core of two ongoing grants to lead training efforts in Nanotechnology

NHLBI - Integrated Nanosystems for Imaging and Therapy (2005-2011; K. Wooley, PI) NCI - The Siteman Center of Cancer Nanotechnology Excellence at Washington University (2005-2010; S. Wickline, PI)

Involved in Education and Training for Molecular Imaging Center grant (D. Piwnica-Worms, PI)

Co-Director: Imaging Sciences Pathway – DBBS (2006-2008) Director: Imaging Sciences Pathway – DBBS (2008-present) Organizing Committee: Imaging Sciences Retreat at Washington University (Chair; April, 2006; 2008-

2010) Organizing Committee: CNST Nanotechnology Workshop 2006, Beckman Institute, University of

Illinois-Urbana/Champaign, May, 2006 Organizing Committee: Nanotechnology and the Life Sciences Workshop, Washington University,

March 30-April 1, 2007 Lead Organizer: Nanotechnology and Imaging Seminar Series (2006-2007; 2007-2008; 2008-

2009; 2010) Moderator: HHMI/NIBIB Interfaces Initiative Workshop (Sept 30-October 2, 2009)

INVITED LECTURES (last 5 years):

1. Copper-64 Radiopharmaceuticals for Cancer Imaging and Therapy. VU University Medical Imaging

Center, Amsterdam, The Netherlands; January 27, 2011. 2. Molecular Imaging of Cancer Metastasis using PET and Optical Methods. AMIE Translational Imaging

Workshop, Keynote Lecture; Erasmus MC, Rotterdam, The Netherlands, January 28, 2011. 3. Receptor targeted radiopharmaceuticals for cancer imaging. University of Pittsburgh Cancer Institute

Seminar, Pittsburgh, PA; June 21, 2011 4. Developing chelators for radiometals. International Symposium of Radiopharmaceutical Sciences,

Workshop Lecture. Amsterdam, The Netherlands; August 28, 2011. 5. Receptor targeted radiopharmaceuticals for cancer imaging. Department of Pharmacology and Chemical

Biology Seminar, Pittsburgh, PA; September 20, 2011

Anderson CV | 20

6. New PET radiopharmaceuticals: applications for imaging tumor receptors and the tumor microenvironment. IPET 2011; IAEA Vienna, Austria. Nov 8, 2011

7. Receptor targeted radiopharmaceuticals for cancer imaging and therapy. University of British Columbia,

Vancouver, BC Canada; January 12, 2012 8. Receptor targeted imaging of cardiovascular disease (Keynote Speaker). University of Ottawa Heart

Institute, Ottawa, ON, Canada; June 21, 2012

9. Molecular Imaging of the Pre-metastatic Niche. Next Generation Medical Imaging, Carnegie Melon University, Pittsburgh, PA September 5, 2012

10. Copper-64 Radiopharmaceuticals for PET imaging of Tuberculosis and Cancer. Oxford University,

Oxford, England, UK. January 31, 2013.

11. Translating Novel Agents for Cancer Imaging into Humans to Better Predict the Presence of a Target on the Tumor. Tumor Imaging and Drug Development workshop sponsored by Hanson Wade; Boston, MA; May 1, 2013

12. Copper-64 Radiopharmaceuticals: Chemistry and Applications to Imaging Cancer Metastasis. Joint

Program in Nuclear Medicine, Harvard Medical School, Boston, MA; May 2, 2013.

13. Molecular Imaging Probe Highlights – Basic Science Summary session, Society of Nuclear Medicine and Molecular Imaging, Vancouver, BC, Canada, June 9, 2013.

14. Molecular Imaging of Cancer Metastasis with Copper-64 Radiopharmaceuticals and PET. Siemens Pre-

clinical Imaging workshop, World Molecular Imaging Conference, Savannah, GA September 20, 2013.

15. Molecular Imaging of Immune Cells in Tuberculosis and Inflammation. Duquesne University, Pittsburgh, PA. April 3, 2014

16. Basic Science Summary – Molecular Imaging Probes. Society of Nuclear Medicine and Molecular

Imaging Conference, St. Louis, MO, June 8, 2014

17. The Latest and Greatest in Radiometal Chelate Chemistry. Society of Nuclear Medicine and Molecular Imaging Conference, St. Louis, MO, June 10, 2014

18. Radiometal-based PET Tracers for Imaging Cancer and Inflammation. Department of Radiology,

Emory University. February 19, 2015

19. Radiometal-labeled Biomolecules for PET Imaging of Disease: Making Informed Choices on Radionuclides and Chelators. World Molecular Imaging Conference, Honolulu, HI; Sept 2, 2015

20. PET imaging and Therapy of Cancer by Targeting Very Late Antigen 4 (VLA-4). Michael J. Welch

Memorial Lecture, Siteman Cancer Center, Washington University, St. Louis; September 18, 2015

21. The Next Generation of PET Tracers for Oncological Imaging. Educational Session, AACR Annual Meeting, April 16, 2016.

22. Radiometals in PET: How Chelate Chemistry Informs in vivo Imaging of Disease. Patricia Durbin

Memorial Lecture, Lawrence Berkeley Laboratory, Berkeley, CA; May 4, 2016

23. Radiometals in PET: How Chelate Chemistry Informs in vivo Imaging of Disease. Department of Chemistry, University of New Hampshire, Durham, NH; May 11, 2016

24. Radiometal-based PET Tracers for Imaging Inflammation in Cancer and Tuberculosis. 121 Bio, Boston,

Anderson CV | 21

MA; May 13, 2016 EDITORIAL RESPONSIBILITIES Editorial Board: Cancer Biotherapy and Radiopharmaceuticals (1999-present) Bioconjugate Chemistry (2000-2011) American Journal of Nuclear Medicine and Molecular Imaging (2011-present) Journal of Nuclear Medicine (2012-2016) Associate Editor: Molecular Imaging and Biology (2015-present) Journal of Nuclear Medicine (2016-present) Reviewer: Nuclear Medicine and Biology Journal of Coordination Chemistry British Journal of Cancer Chemistry and Biology Journal of Medicinal Chemistry Molecular Cancer Therapeutics Peptides, an International Journal Chemistry Reviews International Journal of Cancer Molecular Imaging Radiochimica Acta Clinical and Experimental Metastasis Cancer Research Clinical Cancer Research Molecular Cancer Therapeutics Journal of Inorganic Biochemistry Chemistry and Biology Chemistry Communications

Journal of the American Chemical Society PNAS Nature Medicine Nature Nanotechnology Nature Communications

CURRENT RESEACH SUPPORT: Department of Energy DE-SC-0008833: Integrated Program of Excellence in Nuclear Medicine and Radiochemistry Research; Principal Investigator; Total funds over 4 years - September 1, 2012-August 31, 2016: $1,995,214; (5% effort) NIH P30 CA047904-24, Cancer Center Support Grant (N. Davidson, PI); Co-director, In Vivo Imaging Facility Core; 09/10/97-06/30/20; $120,538 (7.5% effort) NIH 1R21EB017317-01 Solid-phase Platform for the Preparation of Dual-receptor Targeted PET Agents (D. Zeng, PI); Co-investigator; 8/1/13-6/30/15; $421,625 (in NCE; 2% effort) NIH R21 CA180211 Molecular Imaging of Metastatic Potential in SCCHN by Targeting VLA-4 and CXCR4, Principal Investigator; 8/12/13-7/31/15 (in NCE) (10% effort). NIH 1R01AI118195-01A1 PET Probes Targeting Immune Cells for Imaging Tuberculosis; Principal Investigator; 7/1/15-6/30/20; $491,815 (Year 1 direct costs) (20% effort). NIH/NCI SBIR contract Phase I. Development of an Innovative PSMA-targeted Radionuclide therapy for Prostate Cancer; (B. Langton-Webster, PI; Principal investigator on Pitt subcontract) 9/30/15-6/29/16; Phase I subcontract: $66,667 (5% effort) NIH/NCI 5P50CA121973 SPORE in Skin Cancer (J. Kirkwood, PI; Principal Investigator on Developmental Research Project) 3/1/16-2/18/17. (2% effort) NIH/NIBIB 1R21 EB023104 Multimodal (PET/MR/NIR) imaging supported drug delivery in inflammatory diseases; Principal Investigator. *** 7th percentile*** COMPLETED RESEARCH SUPPORT (last 3 years):

Anderson CV | 22

Bill and Melinda Gates Research Foundation: Application of Clinical Imaging Modalities to Tuberculosis Treatment and Transmission. Co-investigator (JoAnne L. Flynn, PI); $11,664, 985 (total funds over 4 years – December 1, 2011-November 30, 2015); (10% effort) NIH R01 CA64475 Receptor-targeted Copper Radiopharmaceuticals for Cancer Imaging and Therapy, 7/1/94-1/31/13, Principal Investigator $192,375 (20% effort) NIH R01 CA093375 Radiopharmaceuticals Based on Cross-Bridged Ligands, Principal Investigator, subcontract to UNH – E.H. Wong, P.I. (1/01/02 to 3/31/12) $109,392 (18% effort) Other research related activities. Include patents granted, editorships, journal refereeing, study section memberships, extra-mural grant reviewing and specialty board memberships: NIH/DOE REVIEWS and WORKSHOPS: 1. NCI/NIH Program Project site visitor: University of California-Davis Medical School April 13-15, 1994 2. NCI/NIH Program Project site visitor: City of Hope Medical Center. October 20-22, 1996 3. NCI/NIH Program Project Review: City of Hope Medical Center. May 15, 1997 4. NIH Special Study Section Reviewer: July 14-15, 1997 5. NIH Special Study Section Reviewer: November 4, 1997 6. NCI/NIH Program Project Review: Garden State Cancer Center. June 22-24, 1998, January 13, 1999 7. NIH Special Study Section Reviewer: March 10-11, 1999 8. NIDDK/NIH Workshop Participant: Imaging Beta Cell Mass in Diabetes; Washington, D.C. April 19-20,

1999 9. NCI/NIH Workshop Participant: Angiogenesis Imaging Methods for Clinical Trials; Lake Tahoe, NV Feb

26-27, 2000 10. NCI/NIH Program Project Reviewer: University of Pennsylvania. June 25-27, 2000. 11. NIGMS/NIH Workshop Invited Speaker: Metals in Medicine, Bethesda, MD; June 28-29, 2000. 12. DOE Study Section: Cell-targeted Cancer Therapy, Arlington, VA; May 2, 2001 13. NCI/NIH Program Project site visitor: City of Hope Medical Center. May 20-22, 2001 14. NCI/NIH Program Project Reviewer: University of Pennsylvania. June 1, 2001 15. NCI/NIH Program Project Reviewer: University of Pennsylvania. October 31, 2001 16. NCI/NIH Program Project Reviewer: City of Hope Medical Center. November 16, 2001 17. NIH Special Study Section Reviewer: November 11-12, 2002; March 10, 2003; March 27, 2003,

November 8, 2004, March 14. 2005, September 8-9, 2005, November 9, 2005, July 10, 2006 18. NCI/NIH Parent Committee D: ad hoc member, August, 2001; December, 2001; April, 2003; August,

2004; April 7, 2005 19. NCI/NIH Program Project Reviewer: UC-Davis Medical Center. January 22, 2003, October 15, 2003 20. NCI/NIH Program Project Review: Garden State Cancer Center. June 2, 2004 21. NIH Special Emphasis Panel: May 2, 2003 (chairperson); July 28, 2004, February 17, 2005 22. NIH Program Project Cluster Review: February 14-16, 2005 23. NIH Medical Imaging (MEDI) study section (ad hoc): May 31, 2007; February 14-15, 2008 24. NIH Medical Imaging (MEDI) study section, charter member: July 2008-June 2009 25. NIH Clinical Molecular Imaging Probes (CMIP) study section charter member: July 2009-June, 2012 26. NIH NCI (Intramural) Molecular Imaging Program reviewer; March, 2012 27. DOE Brookhaven Linear Isotope Production Facility Review; Dec 2012, Nov 2014 28. NCI Omnibus R03/R21 "Cancer Imaging" Special Emphasis Panel; October 25, 2013 (Chairperson) 29. NIH Study Section: Academic-Industrial Partnership study section; November 7, 2013 30. NIH Special Emphasis Panel – Oncology; December 2013; December, 2014 31. NIH: Immune and Radiotherapy Special Emphasis Panel Teleconference Study Section; January 16, 2014 32. DoD: CDMRP Breast Cancer Research Program reviewer; March 12-14, 2014 33. NIH: Cancer Omnibus (R21/R03) Special Emphasis Panel Study Section; March 20-21, 2014 34. NCI Image-Guided Drug Delivery R01 Study Section; October 16, 2014 (Chairperson) 35. NCI Omnibus SEP-14 (R21/R03) Special Emphasis Panel Study Section; June 16, 2015 36. NIBIB 2015-10 U01 Quantum Review Study Section; June 24, 2015. 37. NCI CCSG review – University of Iowa Holden Cancer Center; Nov 2-4, 2015

Anderson CV | 23

38. NCI Omnibus SEP-14 (R21/R03) Special Emphasis Panel Study Section; March 1, 2016 39. NIH Clinical Center Department of Radiology Intramural Review (ad hoc member) March 28-29, 2016

Additional Grant Reviews 1. Cancer Prevention and Research Institute of Texas study section member: January, 2010-2012; 2014- 2. Wellcome Trust ad hoc reviewer, September, 2011 3. Cancer Research UK reviewer, January, 2013, September 2015 Additional Research-related Activities 1. Steering Committee on IAEA International Conference on 2007

“Molecular Nuclear Medicine and Clinical PET”, Bangkok, Thailand 2. Consultant to the International Atomic Energy Agency (IAEA) 2006-2009 3. NCI Translates Scientific Organizing Committee 2009 4. NIH NIBIB Board of Scientific Councilors 2010- 5. National Academy of Sciences Committee on Assuring a Future 2011-2012

US-based Nuclear Chemistry Expertise

6. Co-Chair, SNMMI/AACR conference, “State-of-the-Art Molecular 2012-2013 Imaging in Cancer Biology”, San Diego, CA Feb 27-March 2, 2013

7. Nuclear Sciences Advisory Committee, subcommittee on Reviewing the 2014- Global Threat Reduction Initiative; Molybdenum-99 program

8. Co-Chair, SNMMI/AACR conference, “State-of-the-Art Molecular 2014-2015 Imaging in Cancer Biology”, San Diego, CA Feb 11-14, 2015

SERVICE: University and Medical School Imaging Center Dedication Committee, Mallinckrodt Institution of Radiology 1993-1994 Animal Studies Committee, Washington University School of Medicine 1993-1998 Washington University Cancer Center, Full Member 1996-2011 Washington University Division of Biology and Biomedical Sciences- 1999-2003 Graduate Programs Admissions Committee Human Studies Committee – Continuing Review Committee 2002-2004 Washington University Executive Committee, Division of Radiological Sciences 2007-2011 Mallinckrodt Institution of Radiology Washington University Medical Scientist Training program (MSTP; MD/PhD) 2009-2010 Admissions committee